Tumor Regression Grade in Gastric Cancer After Preoperative Therapy.
AJCC
Chemoradiation therapy
Gastric cancer
Neoadjuvant therapy
Preoperative therapy
Tumor regression grade
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
12
2019
accepted:
04
06
2020
pubmed:
17
6
2020
medline:
10
7
2021
entrez:
17
6
2020
Statut:
ppublish
Résumé
The Cancer Staging Manual, 8th edition, now includes post-neoadjuvant therapy (ypTNM) staging for gastric cancer patients. Our purpose was to determine whether the tumor regression grade (TRG) of the primary tumor is useful for predicting the survival of these patients. We performed a retrospective review of an institutional database and identified patients with clinically non-metastatic gastric adenocarcinoma who underwent preoperative chemotherapy or chemoradiation therapy before gastrectomy. Pathology reports were reviewed, and TRG was classified as follows: 0 (complete response), 1 (viable tumor cells ≤ 1-2%), 2 (viable cells ≤ 50%), or 3 (viable cells > 50%). Of the 356 patients identified, including 80 (23%) with a gastroesophageal junction tumor, 268 (75%) had undergone preoperative chemoradiation therapy. Fifty-six (16%) had TRG 0, 57 (16%) TRG 1, 128 (36%) TRG 2, and 115 (32%) TRG 3. No association between TRG and pretreatment factors was identified, except for signet-ring cell histologic type and tumor location. A higher TRG was associated with more advanced ypT and ypN categories (both p < 0.001), ypM1 (p = 0.004), and R1 resection (p = 0.052). The median overall survival (OS) duration was 6.6 years, and the 5-year OS rate was 54.1%. TRG 3 was associated with a shorter OS duration than were other TRG scores (p = 0.015), while the OS did not differ significantly among the TRG 0-2 groups (p = 0.803). On multivariable analysis, TRG was not associated with OS after adjustment for ypN status. In gastric cancer patients who underwent preoperative therapy, TRG 3 was associated with advanced ypStage and R1 resection. Patients with TRG 3 had a shorter OS duration because of associated advanced ypStage, particularly ypN+ status.
Sections du résumé
BACKGROUND
The Cancer Staging Manual, 8th edition, now includes post-neoadjuvant therapy (ypTNM) staging for gastric cancer patients. Our purpose was to determine whether the tumor regression grade (TRG) of the primary tumor is useful for predicting the survival of these patients.
METHODS
We performed a retrospective review of an institutional database and identified patients with clinically non-metastatic gastric adenocarcinoma who underwent preoperative chemotherapy or chemoradiation therapy before gastrectomy. Pathology reports were reviewed, and TRG was classified as follows: 0 (complete response), 1 (viable tumor cells ≤ 1-2%), 2 (viable cells ≤ 50%), or 3 (viable cells > 50%).
RESULTS
Of the 356 patients identified, including 80 (23%) with a gastroesophageal junction tumor, 268 (75%) had undergone preoperative chemoradiation therapy. Fifty-six (16%) had TRG 0, 57 (16%) TRG 1, 128 (36%) TRG 2, and 115 (32%) TRG 3. No association between TRG and pretreatment factors was identified, except for signet-ring cell histologic type and tumor location. A higher TRG was associated with more advanced ypT and ypN categories (both p < 0.001), ypM1 (p = 0.004), and R1 resection (p = 0.052). The median overall survival (OS) duration was 6.6 years, and the 5-year OS rate was 54.1%. TRG 3 was associated with a shorter OS duration than were other TRG scores (p = 0.015), while the OS did not differ significantly among the TRG 0-2 groups (p = 0.803). On multivariable analysis, TRG was not associated with OS after adjustment for ypN status.
CONCLUSION
In gastric cancer patients who underwent preoperative therapy, TRG 3 was associated with advanced ypStage and R1 resection. Patients with TRG 3 had a shorter OS duration because of associated advanced ypStage, particularly ypN+ status.
Identifiants
pubmed: 32542556
doi: 10.1007/s11605-020-04688-2
pii: 10.1007/s11605-020-04688-2
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1380-1387Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015;1(4):505-27. doi: https://doi.org/10.1001/jamaoncol.2015.0735 .
Badgwell B. Multimodality Therapy of Localized Gastric Adenocarcinoma. J Natl Compr Canc Netw 2016;14(10):1321-7.
doi: 10.6004/jnccn.2016.0139
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med 2006;355(1):11-20. doi: https://doi.org/10.1056/NEJMoa055531 .
doi: 10.1056/NEJMoa055531
pubmed: 16822992
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. The New England journal of medicine. 2001;345(10):725-30. doi: https://doi.org/10.1056/NEJMoa010187 .
doi: 10.1056/NEJMoa010187
pubmed: 11547741
Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(13):1715-21. doi: https://doi.org/10.1200/JCO.2010.33.0597 .
doi: 10.1200/JCO.2010.33.0597
Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(14):2774-80. doi: https://doi.org/10.1200/JCO.2004.01.015 .
doi: 10.1200/JCO.2004.01.015
Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(24):3953-8. doi: https://doi.org/10.1200/JCO.2006.06.4840 .
doi: 10.1200/JCO.2006.06.4840
Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF et al. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017. doi: https://doi.org/10.1007/s10120-017-0743-4 .
Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK et al. AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer; 2017.
doi: 10.1007/978-3-319-40618-3
Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF et al. The ypT category does not impact overall survival in node negative gastric cancer. Journal of surgical oncology. 2018;117(8):1721-8. doi: https://doi.org/10.1002/jso.25081 .
doi: 10.1002/jso.25081
pubmed: 29949666
pmcid: 7703861
Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Annals of surgery. 1999;229(3):303-8. doi: https://doi.org/10.1097/00000658-199903000-00001 .
doi: 10.1097/00000658-199903000-00001
pubmed: 10077040
pmcid: 1191693
Blackham AU, Greenleaf E, Yamamoto M, Hollenbeak C, Gusani N, Coppola D et al. Tumor regression grade in gastric cancer: Predictors and impact on outcome. Journal of surgical oncology. 2016;114(4):434-9. doi: https://doi.org/10.1002/jso.24307 .
doi: 10.1002/jso.24307
pubmed: 27199217
Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Annals of surgical oncology. 2007;14(12):3412-8. doi: https://doi.org/10.1245/s10434-007-9574-6 .
doi: 10.1245/s10434-007-9574-6
pubmed: 17909917
Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Annals of surgical oncology. 2012;19(6):1936-43. doi: https://doi.org/10.1245/s10434-011-2165-6 .
doi: 10.1245/s10434-011-2165-6
pubmed: 22187120
Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T et al. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. British journal of cancer. 2014;110(7):1712-20. doi: https://doi.org/10.1038/bjc.2014.94 .
doi: 10.1038/bjc.2014.94
pubmed: 24569472
pmcid: 3974097
Mingol F, Gallego J, Orduna A, Martinez-Blasco A, Sola-Vera J, Moya P et al. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg. 2015;15:66. doi: https://doi.org/10.1186/s12893-015-0054-9 .
doi: 10.1186/s12893-015-0054-9
pubmed: 25997454
pmcid: 4440567
Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA et al. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Annals of surgical oncology. 2018;25(7):2012-7. doi: https://doi.org/10.1245/s10434-018-6471-0 .
doi: 10.1245/s10434-018-6471-0
pubmed: 29748883
pmcid: 7703854
Ikoma N, Das P, Blum M, Estrella JS, Devine CE, Wang X et al. Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. International journal of radiation oncology, biology, physics. 2017;99(3):660-6. doi: https://doi.org/10.1016/j.ijrobp.2017.07.018 .
doi: 10.1016/j.ijrobp.2017.07.018
pubmed: 29280460
Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Annals of surgical oncology. 2017;24(9):2679-87. doi: https://doi.org/10.1245/s10434-017-5838-y .
doi: 10.1245/s10434-017-5838-y
pubmed: 28332034
Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF et al. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018;21(1):74-83. doi: https://doi.org/10.1007/s10120-017-0743-4 .
doi: 10.1007/s10120-017-0743-4
John P. Klein MLM. Survival Analysis: Techniques for Censored and Truncated Data (Statistics for Biology and Health). Springer; 2005.
JDavid W. Hosmer J, Stanley Lemeshow. Applied Logistic Regression, 3rd Edition. Wiley; 2013.
Therneau, TM and Grambsch P. Modeling Survival Data. New York, Springer, 2000.
Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2018;21(6):1004-13. doi: https://doi.org/10.1007/s10120-018-0832-z .
doi: 10.1007/s10120-018-0832-z
Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of surgical oncology. 2017;24(8):2252-8. doi: https://doi.org/10.1245/s10434-017-5830-6 .
doi: 10.1245/s10434-017-5830-6
pubmed: 28337660
Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A et al. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. Journal of the American College of Surgeons. 2015;221(1):83-90. doi: https://doi.org/10.1016/j.jamcollsurg.2015.04.004 .
doi: 10.1016/j.jamcollsurg.2015.04.004
pubmed: 26002780
Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W et al. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. Cancer. 2018;124(5):998-1007. doi: https://doi.org/10.1002/cncr.31155 .
doi: 10.1002/cncr.31155
pubmed: 29393964
pmcid: 5937252